LONGUEUIL, QC, Aug. 30, 2012 /PRNewswire/ - During the course of this summer, which is fast drawing to a close, Agropur Cooperative posted excellent results at numerous international cheese competitions, garnering 19 prizes, including 9 first-place finishes, at events such as the one hosted by the American Cheese Society, the Wisconsin State Fair and the International Cheese Awards. Following on the successes of recent years, the Cooperative was recognized for the quality and excellence of many of its cheese at these major competitions.
According to Robert Coallier, CEO of Agropur: "Backed by close to 75 years of experience and advances in the dairy industry, our Cooperative continues to redouble its efforts to expand and improve its line of fine cheeses. We can always rely on our master cheesemakers and outstanding teams to propel us to new heights on the national and international stage years after year, and to provide our customers with exceptional products."
American Cheese Society In Raleigh, North Carolina, August 1 to 4, 2012 The objective of this event is to support North American artisans and the cheese industry as a whole. Founded in 1983, the ACS provides education, business development and networking opportunities for targeted members of the industry, while continuously striving to improve the quality and availability of their cheeses throughout North America.
Prizes won by Agropur at the American Cheese Society:
1st place
Rondoux Triple Cr?me, in the Triple Cr?me - soft ripened/cream added - all milks category
All?gro probio 7 %, in the Fat Free and Low Fat cheeses category
2nd place
Chevalier Triple Cr?me, in the Triple Cr?me - soft ripened/cream added - all milks category
OKA with Mushrooms, in the Cheeses flavored with herbs, fruits, vegetables, truffles, flowers, syrups - all milks category
OKA Raclette, in the Open Category - made from cow's milk
3rd place:
Brie Normandie, in the Brie - made from cow's milk category
Grand Camembert L'Extra, in the Camembert - made from cow's milk category
Champfleury, in the Open Category - made from cow's milk
Wisconsin State Fair In West Allis, Wisconsin, June 21, 2012 This event, which is organized for Wisconsin producers, showcased close to 300 products in 26 different categories. The two facilities that Agropur operates in the state of Wisconsin were in the running, and earned the following awards:
1st place:
Cheddar, in the Mild Cheddar category
Mozzarella, in the Mozzarella category
Feta, in the Feta category
Feta, basil and tomato, in the Flavored Soft Cheese category
2nd place:
Feta, basil and tomato, in the Flavored Soft Cheese category
3rd place:
Mozzarella, in the Mozzarella category
Peppercorn Feta, in the Flavored Soft Cheese category
International Cheese Awards In Nantwich, United Kingdom, July 25, 2012 The ICA, which is the largest competition of its kind, has been around for 115 years. A total of 156 expert judges were tasked with judging close to 4,000 cheeses from 27 countries.
Agropur performed extremely well, winning awards for its Grand Cheddar: Gold in the "Best Overseas Cheese" category and Gold in the "Cheese made from unpasteurised milk" category. In addition, the Cooperative was awarded the John Webb Trophy for the "Best cheese made from unpasteurised milk".
About Agropur Founded in 1938, Agropur is a leader in the Canadian dairy industry. With sales of $3.6?billion, the Cooperative is a source of pride for its 3,349 dairy producer members and 5,700 employees. Agropur processes more than 3 billion litres of milk per year in its 27 plants located in Canada, the United States and Argentina. It markets an impressive line of products, including such well-known brands as Natrel, Qu?bon, Oka, Sealtest and Island Farms.
To learn more about Agropur, please visit www.agropur.com.
Q: Who is responsible in CT if you are a buyer in a for sale by owner? My real estate agent is not getting the purchase done. We are approved for over asking price and he keeps avoiding making the deal? Does the seller in this situation still pay for agent percentage? ? JillmaeSebastian, Ellington, CT
A: Most For Sale by Owners don?t want to pay a commission. So your Realtor is most likely working for free unless you have an arrangement to compensate them. When you buy a for sale by owner you usually aren?t having any realtors involved which is very risky. convincing the seller to pay a commission can also be tricky. Good Luck! Rosanne Nitti is a Realtor? with RMN Investments & Realty Services in Laguna Beach, CA.
A: When purchasing a For Sale by Owner, your agent should be representing you. You need to ask your agent why a Purchase Contract has not be written up between you and the seller. A For Sale By Owner is not obligated to pay an agent commission unless there is something in writing. Sandy Straley is a Realtor? in Layton, UT.
Are you interested in having a qualified REALTOR answer your questions? Click through to Ask a REALTOR? now.
Are you a REALTOR who would like to answer consumer questions? Click through to become an Ask a REALTOR? participant.
Related posts:
How Do I Purchase A For Sale By Owner Home When I Have A Buyer?s Agent?
Should I Use A Realtor To Buy A For Sale By Owner Home?
If We Look At FSBO Houses Will We Still Owe Commission To Our Realtor?
Can A Broker Who Is Buying A Property Directly From A Seller Also Collect A Commission?
Can a Listing Agent Act As The Buyer?s Agent In A Short Sale?
For the maintenance of your home, you need to look out for the best professionals there are in the business. While there are several jobs that you will be able to undertake on your own, there are a few that need the expert eye of a professional. One of these is the electrical work of your home.
Electrical services in South London are plenty and you will have no problem narrowing down on a service provider of your choice. Your assessment will have to be broadly based on where they are located, the services they provide, the price at which they work and the quality of the work done. To find a service that best suits you, it would make sense to ask for recommendations. Using these will help you find a service that has been tried and tested.
Many people who are comfortable with DIY projects may wonder on the need for a professional for such jobs. While changing a bulb or fuse is simple enough, fixing a broken socket or working on rewiring is much more complicated. If these jobs are not done the right way, they can prove to be dangerous. You or a member of the family could suffer from a shock, or you could end up creating a fire hazard. There are also chances that you end up with a short circuit, plunging the whole house in darkness.
To avoid all of this, calling in the expert would be a good idea. Such professionals will be well versed with the trade and will also be able to analyse a particular electrical set up. They will be able to anticipate any issues that may arise. They also come prepared for almost all scenarios, something which you will not always be able to do.
Some of the services that you should look out for are availability of the service over weekends, late nights and public holidays. Some services charge for this facility, but it is a worthwhile one to have. You should also be able to discuss the quality of materials being used and the guarantee on how long they will last. Ask for references that are within a three year bracket. Call up these references and ask about the quality of work and the promptness of completion.
Once you are satisfied with all aspects, it would be best to get the work detailed out in a written agreement.
Electricians south london provide safe and practical electrical installations. Visit Electrical Initiative, is a full service, highly professional electrical contracting company. For more detail vist our website www.electriciansouthlondon.com
This article has been viewed 12 time(s).
It is a violation of our terms and conditions for writers to submit material which they did not write and claim it as their own.
If this article infringes on your copyrights, you MUST either call us at 706-866-2295 or send proof of infringement
along with the offending article's title, URL, and writer name to
IdeaMarketers.com
Attn: Marnie Pehrson - Copyright Concern
514 Old Hickory Ln
Ringgold GA 30736 USA
If you email us or use our problem submission form, we CANNOT guarantee we'll receive your notice!
Four-time Grammy Award winner and former CMA Entertainer of the Year honoree Keith Urban will participate in a special Country Music Hall of Fame? and Museum educational program for selected Metro Nashville Public School high school students on Thursday, September 6th, at 10:00 a.m. CDT.?All Access: Keith Urban will take place in the museum?s Ford Theater.???
Although the program is not open to the public and the school registration period is closed, the event will be live-streamed at www.countrymusichalloffame.org and www.keithurban.net.?? Interested educators and music fans are encouraged to watch online.? The 75-minute program will be moderated by Museum Editor Michael Gray.?
?We?re thrilled to offer music and arts students from several Metro Nashville Public Schools the chance to get ?up close and personal? with one of country music?s great talents, Keith Urban,? said Ali Tonn, the museum?s director of education and public programs.? ?In this special program, students will hear Keith talk about the craft of songwriting, his influences and creative inspirations, seminal moments in his career and more.? They will also have the opportunity to ask him questions.? This program is the first of its kind for the museum and will serve as a ?pilot? of sorts; we hope to be able to offer more All Access educational programs when our museum expansion is completed in 2014.??
Urban has for years been a generous supporter of the museum:? His annual We?re All for the Hall concerts, which began in 2009, have raised approximately $1.5 million to date, and exponentially increased awareness of the institution and its mission.?
Harvard scientists have, for the first, time created a type of "cyborg" tissue by embedding a three-dimensional network of functional, bio-compatible nanoscale wires into engineered human tissues.
As described in a paperpublished August 26 in Nature Materials, a multi-institutional research team led by Charles M. Lieber, the Mark Hyman, Jr. Professor of Chemistry at Harvard and Daniel Kohane, a Harvard Medical School professor in the Department of Anesthesia at Children's Hospital Boston developed a system for creating nanoscale "scaffolds" which could be seeded with cells which later grew into tissue.
Also contributing to the work were Robert Langer, from the Koch Institute at the Massachusetts Institute of Technology, and Zhigang Suo, the Allen E. and Marilyn M. Puckett Professor of Mechanics and Materials at Harvard's School of Engineering and Applied Sciences.
"The current methods we have for monitoring or interacting with living systems are limited," said Lieber. "We can use electrodes to measure activity in cells or tissue, but that damages them. With this technology, for the first time, we can work at the same scale as the unit of biological system without interrupting it. Ultimately, this is about merging tissue with electronics in a way that it becomes difficult to determine where the tissue ends and the electronics begin."
The research addresses a concern that has long been associated with work on bioengineered tissue ? how to create systems capable of sensing chemical or electrical changes in the tissue after it has been grown and implanted. The system might also represent a solution to researchers' struggles in developing methods to directly stimulate engineered tissues and measure cellular reactions.
"In the body, the autonomic nervous system keeps track of pH, chemistry, oxygen and other factors, and triggers responses as needed," Kohane explained. "We need to be able to mimic the kind of intrinsic feedback loops the body has evolved in order to maintain fine control at the cellular and tissue level."
Using the autonomic nervous system as inspiration, Bozhi Tian, a former doctoral student under Lieber and former postdoctoral fellow in the Kohane and Langer labs, and collaborator Jia Liu worked in Lieber's lab at Harvard to build mesh-like networks of nanoscale silicon wires?about 30 - 80 nm in diameter?shaped like flat planes or in a reticular conformation.
The process of building the networks, Lieber said, is similar to that used to etch microchips.
Beginning with a two-dimensional substrate, researchers laid out a mesh of organic polymer around nanoscale wires, which serve as the critical nanoscale sensing elements. Nanoscale electrodes, which connect the nanowire elements, were then built within the mesh to enable nanowire transistors to measure the activity in cells without damaging them. Once complete, the substrate was dissolved, leaving researchers with a net-like sponge or a mesh that can be folded or rolled into a host of three dimensional shapes.
Once complete, the networks were porous enough to allow the team to seed them with cells and encourage those cells to grow in 3D cultures.
"Previous efforts to create bioengineered sensing networks have focused on two-dimensional layouts, where culture cells grow on top of electronic components, or on conformal layouts where probes are placed on tissue surfaces," said Tian. "It is desirable to have an accurate picture of cellular behavior within the 3D structure of a tissue, and it is also important to have nanoscale probes to avoid disruption of either cellular or tissue architecture."
Using heart and nerve cells, the team successfully engineered tissues containing embedded nanoscale networks without affecting the cells' viability or activity. Using the embedded devices, they were able to detect electrical signals generated by cells deep within the tissue, and to measure changes in those signals in response to cardio- or neuro-stimulating drugs.
Researchers were also able to construct bioengineered blood vessels, and used the embedded technology to measure pH changes ? as would be seen in response to inflammation, ischemia and other biochemical or cellular environments ? both inside and outside the vessels.
Though a number of potential applications exist for the technology, the most near-term use, Lieber said, may come from the pharmaceutical industry, where researchers could use the technology to more precisely study how newly-developed drugs act in three dimensional tissues, rather than thin layers of cultured cells. The system might also one day be used to monitor changes inside the body and react accordingly, whether through electrical stimulation or the release of a drug.
###
Harvard University: http://www.harvard.edu
Thanks to Harvard University for this article.
This press release was posted to serve as a topic for discussion. Please comment below. We try our best to only post press releases that are associated with peer reviewed scientific literature. Critical discussions of the research are appreciated. If you need help finding a link to the original article, please contact us on twitter or via e-mail.
Advances in ataxia research to be featured at USF's Innovative Learning and Simulation CenterPublic release date: 28-Aug-2012 [ | E-mail | Share ]
Contact: Anne DeLotto Baier abaier@health.usf.edu 813-974-3303 University of South Florida (USF Health)
Friedreich's Ataxia Research Alliance and University of South Florida host Sept. 6 live streamed event
Tampa, FL (Aug. 27, 2012) Scientists, clinicians and patients will gather at the University of South Florida's Center for Advanced Medical Learning and Simulation (CAMLS) in downtown Tampa Sept. 6 to share research insights and energize the search for a cure for Friedreich's ataxia and related disorders.
The fourth annual scientific symposium "Understanding a Cure" will be held from 6 to 8 p.m. on Thursday, Sept. 6, at USF Health CAMLS, 124 South Franklin Street, Tampa, FL 33602. The symposium, free and open to the public, is hosted by Friedreich Ataxia Research Alliance (FARA) and the USF Ataxia Research Center (ARC), and will include a tour of CAMLS.
This year, for the first time, the scientific symposium will be live streamed through the FARA Facebook page, with opportunities for visitors to join the discussion long distance. To connect to the live stream and learn about cutting edge research advances in Friedreich's ataxia, visit: http://www.facebook.com/CureFA/app_196506863720166 on September 6 at 6 p.m. A Facebook account is not needed to join.
Friedreich's ataxia is a rare, debilitating neuromuscular disorder. Symptoms, typically emerging between ages 5 and 15, often progress to severe disability and include the following: loss of coordination and muscle weakness that leads to wheelchair use, energy deprivation and fatigue, vision impairment, hearing loss, slurred speech, aggressive scoliosis, diabetes, and life-shortening cardiac disease. There is not yet an approved treatment or a cure.
"This year's Friedreich's Ataxia Symposium will build upon the momentum of the last three years by highlighting some of the most promising discoveries yet from leading researchers in the field," said Theresa Zesiewicz, MD, professor of neurology and director of the University of South Florida Ataxia Research Center, who moderates the symposium. "The opportunity for patients who cannot be with us in person to join the interactive symposium in real-time via Facebook has generated a lot of excitement. We're looking forward to lively discussions."
Symposium speakers will include Helene Puccio, PhD, research director for INSERM, Department of Translational Medicine and Neurogenetics, Institute of Genetics and Molecular and Cellular Biology (IMCBG) in Illkirch, France. Dr. Puccio's laboratory develops animal and cell models to help understand the pathophysiology of Friedreich's ataxia and the function of frataxin, a protein severely deficient in people with Friedreich's ataxia. The preclinical models are used by Puccio and other researchers worldwide searching for potential new treatment approaches to ataxias, including gene replacement therapy.
Pediatric cardiologist R. Mark Payne, MD, professor of pediatrics and medical and molecular genetics director at Wells Center for Pediatric Research-Indiana University School of Medicine, will share his expertise on cardiomyopathy, or deterioration of heart muscle, related to Friedreich's ataxia. Dr. Payne conducts research on heart disease caused by mitochondrial defects.
Guy Miller, MD, PhD, CEO of Edison Pharmaceuticals, Inc., will speak about advances in developing drugs to treat mitochondrial diseases that share a common feature defects in how the body makes and regulates energy metabolism.
FARA President Ron Bartek and Jennifer Farmer, FARA executive director, will address progress nationwide in the research and management of Friedreich's ataxia.
Stephen Klasko, MD, CEO for USF Health and dean of the Morsani College of Medicine, will moderate a panel discussion on patients' perspectives of living with ataxias.
USF is one of 11 sites included in FARA's Collaborative Clinical Research Network, an international network of centers that share data and resources to advance treatments and clinical research for people with Friedreich's ataxia.
###
For more information about the symposium, please call (813) 974-5909.
- About USF Health
USF Health is dedicated to creating a model of health care based on understanding the full spectrum of health. It includes the University of South Florida's colleges of Medicine, Nursing, Public Health and Pharmacy, the School of Biomedical Sciences and the School of Physical Therapy and Rehabilitation Sciences; and the USF Physician's Group. Ranked 34th in federal research expenditures for public universities by the National Science Foundation, the University of South Florida is a high impact global research university.
- About The Friedreich's Ataxia Research Alliance (FARA) -
FARA is a non-profit organization dedicated to curing FA through research. FARA grants and activities provide support for basic and translational FA research, pharmaceutical/biotech drug development, clinical trials, and scientific conferences. For more information, go to www.curefa.org.
[ | E-mail | Share ]
?
AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert! system.
Advances in ataxia research to be featured at USF's Innovative Learning and Simulation CenterPublic release date: 28-Aug-2012 [ | E-mail | Share ]
Contact: Anne DeLotto Baier abaier@health.usf.edu 813-974-3303 University of South Florida (USF Health)
Friedreich's Ataxia Research Alliance and University of South Florida host Sept. 6 live streamed event
Tampa, FL (Aug. 27, 2012) Scientists, clinicians and patients will gather at the University of South Florida's Center for Advanced Medical Learning and Simulation (CAMLS) in downtown Tampa Sept. 6 to share research insights and energize the search for a cure for Friedreich's ataxia and related disorders.
The fourth annual scientific symposium "Understanding a Cure" will be held from 6 to 8 p.m. on Thursday, Sept. 6, at USF Health CAMLS, 124 South Franklin Street, Tampa, FL 33602. The symposium, free and open to the public, is hosted by Friedreich Ataxia Research Alliance (FARA) and the USF Ataxia Research Center (ARC), and will include a tour of CAMLS.
This year, for the first time, the scientific symposium will be live streamed through the FARA Facebook page, with opportunities for visitors to join the discussion long distance. To connect to the live stream and learn about cutting edge research advances in Friedreich's ataxia, visit: http://www.facebook.com/CureFA/app_196506863720166 on September 6 at 6 p.m. A Facebook account is not needed to join.
Friedreich's ataxia is a rare, debilitating neuromuscular disorder. Symptoms, typically emerging between ages 5 and 15, often progress to severe disability and include the following: loss of coordination and muscle weakness that leads to wheelchair use, energy deprivation and fatigue, vision impairment, hearing loss, slurred speech, aggressive scoliosis, diabetes, and life-shortening cardiac disease. There is not yet an approved treatment or a cure.
"This year's Friedreich's Ataxia Symposium will build upon the momentum of the last three years by highlighting some of the most promising discoveries yet from leading researchers in the field," said Theresa Zesiewicz, MD, professor of neurology and director of the University of South Florida Ataxia Research Center, who moderates the symposium. "The opportunity for patients who cannot be with us in person to join the interactive symposium in real-time via Facebook has generated a lot of excitement. We're looking forward to lively discussions."
Symposium speakers will include Helene Puccio, PhD, research director for INSERM, Department of Translational Medicine and Neurogenetics, Institute of Genetics and Molecular and Cellular Biology (IMCBG) in Illkirch, France. Dr. Puccio's laboratory develops animal and cell models to help understand the pathophysiology of Friedreich's ataxia and the function of frataxin, a protein severely deficient in people with Friedreich's ataxia. The preclinical models are used by Puccio and other researchers worldwide searching for potential new treatment approaches to ataxias, including gene replacement therapy.
Pediatric cardiologist R. Mark Payne, MD, professor of pediatrics and medical and molecular genetics director at Wells Center for Pediatric Research-Indiana University School of Medicine, will share his expertise on cardiomyopathy, or deterioration of heart muscle, related to Friedreich's ataxia. Dr. Payne conducts research on heart disease caused by mitochondrial defects.
Guy Miller, MD, PhD, CEO of Edison Pharmaceuticals, Inc., will speak about advances in developing drugs to treat mitochondrial diseases that share a common feature defects in how the body makes and regulates energy metabolism.
FARA President Ron Bartek and Jennifer Farmer, FARA executive director, will address progress nationwide in the research and management of Friedreich's ataxia.
Stephen Klasko, MD, CEO for USF Health and dean of the Morsani College of Medicine, will moderate a panel discussion on patients' perspectives of living with ataxias.
USF is one of 11 sites included in FARA's Collaborative Clinical Research Network, an international network of centers that share data and resources to advance treatments and clinical research for people with Friedreich's ataxia.
###
For more information about the symposium, please call (813) 974-5909.
- About USF Health
USF Health is dedicated to creating a model of health care based on understanding the full spectrum of health. It includes the University of South Florida's colleges of Medicine, Nursing, Public Health and Pharmacy, the School of Biomedical Sciences and the School of Physical Therapy and Rehabilitation Sciences; and the USF Physician's Group. Ranked 34th in federal research expenditures for public universities by the National Science Foundation, the University of South Florida is a high impact global research university.
- About The Friedreich's Ataxia Research Alliance (FARA) -
FARA is a non-profit organization dedicated to curing FA through research. FARA grants and activities provide support for basic and translational FA research, pharmaceutical/biotech drug development, clinical trials, and scientific conferences. For more information, go to www.curefa.org.
[ | E-mail | Share ]
?
AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert! system.
Shares of Nokia Corp. surged on Monday after a Wall Street analyst said that the Finnish phone maker could benefit from the $1 billion patent verdict against Samsung. The decision could delay technology developments for devices that, like Samsung phones, run Google Inc.'s Android operating system. That could boost Nokia's line of Windows Phone-based smartphones.
THE SPARK: A federal jury in San Jose Friday found that some of Samsung Electronics Co.'s products illegally copied features and designs from Apple Inc.'s iPhone and iPad.
THE BIG PICTURE: Nokia was the world's leading mobile phone maker for more than a decade but was was overtaken by Samsung in the first quarter, according to research firm Gartner. The company has been fighting fierce competition from the iPhone and Android-based smartphones.
As part of its turnaround effort, it has based its new smartphone line on Microsoft Corp.'s Windows Phone operating system, not on the popular Android system. But sales of phones using Windows Phone have been slow.
THE ANALYSIS: The verdict against Samsung could give Nokia an edge. The Windows Phone is substantially different from Apple's iPhone operating system and hasn't landed in its legal sights, and some Wall Street analysts say that the verdict against Samsung is likely to slow growth of smartphones that run on Android.
Phones made by Samsung, HTC, LG and Motorola, now a division of Google, use Android.
In a research note published Monday, Wunderlich Securities analyst Matthew Robison echoed that outlook, saying that the $1 billion verdict and possible punitive damages could slow or postpone Android innovation. And any damage to Android favors Nokia's smartphone business, he wrote.
Robison also assumes that smartphone features that were central in Apple's successful patent claims against Samsung will not be contested by Apple on Windows Phone products, noting that Apple and Microsoft have reached agreements on some patents.
"We believe this implies a significant positive shift in application developer sentiment toward Windows Phone," Robison wrote.
But Nokia may face increased competition from Android phones in markets outside the U.S., where prospects for future patent claims by Apple are more remote, Robison said.
The analyst raised his price target for Nokia to 2.50 euros ($3.13) from 2 euros ($2.50). He kept a "Hold" on the stock.
Nokia did not immediately respond to a message seeking comment.
SHARE ACTION: Nokia's U.S.-traded shares gained 20 cents, or 6.5 percent, to $3.28 in afternoon trading. Shares have lost 36 percent of their value this year.
![[ Back to EurekAlert! ]](http://www.eurekalert.org/images/back2e.gif){kind=small}
Public release date: 28-Aug-2012
Share ]